Table 3.
Reported COVID-19 symptoms and signs and SARS-CoV-2 testing by GBA genotype group.
| All patients (N = 181)a |
Type 1 GD N370S/N370S or N370S/R496H (n = 121) |
Type 1 GD Other genotypesb (n = 57) |
|
|---|---|---|---|
| Any COVID-19 Symptoms, no. (%) | 45 (25) | 31 (26) | 14 (25) |
| Any 3+ COVID-19 Symptoms, no. (%) | 18 (10) | 14 (12) | 4 (7) |
| Cough | 17 (9) | 15 (12) | 2 (4) |
| Fevers | 23 (13) | 18 (15) | 5 (9) |
| Chills, night sweats | 8 (4) | 6 (5) | 2 (4) |
| Very tired | 16 (9) | 9 (7) | 7 (12) |
| Achy | 11 (6) | 7 (6) | 4 (7) |
| Abdominal pain | 1 (1) | – | 1 (2) |
| Diarrhea | 4 (2) | 4 (3) | – |
| Not able to taste | 6 (3) | 5 (4) | 1 (2) |
| Not able to smell | 7 (4) | 5 (4) | 2 (4) |
| Bruising | – | – | – |
| Chest pain | 2 (1) | 1 (1) | 1 (2) |
| Feeling short of breath | 4 (2) | 2 (2) | 2 (4) |
| COVID-19 toes | 1 (1) | 1 (1) | – |
| Extreme exhaustion | 8 (4) | 6 (5) | 2 (4) |
| Weakness | 13 (7) | 10 (8) | 3 (5) |
| Other | 8 (4) | 7 (6) | 1 (2) |
| SARS-CoV-2 testing, no. (%) | 77 (43) | 56 (46) | 21 (37) |
| NATc | 34 (19) | 23 (19) | 11 (19) |
|
5 (16) 5 (100) - |
5 (24) 5 (100) - |
- - - |
|
27 (84) 3 (11) 24 (89) |
16 (76) 3 (19) 13 (81) |
11 (100) - 11 (100) |
| Antibody testingd | 61 (33) | 45 (37) | 16 (28) |
|
15 (25) 9 (60) 6 (40) |
13 (30) 8 (62) 5 (38) |
2 (13) 1 (50) 1 (50) |
|
42 (70) 3 (7) 39 (93) |
29 (66) 3 (10) 26 (90) |
13 (81) - 13 (100) |
Grouping by genotype was based on expected phenotype, with GBA N370S/N370S or N370S/R496H manifesting as mild GD and other genotypes leading to moderate to severe GD.
a
‘All patients’ column includes 3 patients with Type 3 GD
b
Other genotypes included: N370S/84GG, N370S/L444P, N370S/D409H, N370S/IVS2+1, R496H/84GG, N370S/G202R, N370S/D409G, N370S/G195E, N370S/G377S, N370S/R463H, N370S/V394L, R463C/R463C, R496H/IVS2+1, L444P/P198R.
c
Survey referred to this as ‘PCR test’.
d
Four respondents indicated they had antibody testing but no test result was reported.